BACKGROUND: Hereditary haemorrhagic telangiectasia (HHT) is an autosomal dominant vascular dysplasia characterised by mucocutaneous telangiectasis, epistaxis, gastrointestinal haemorrhage, and arteriovenous malformations in the lung and brain. Causative mutations for HHT have been identified in two genes, endoglin and ALK1, which encode proteins involved in serine-threonine kinase signalling in the endothelial cell. METHODS: A number of people affected with HHT had completed a postal questionnaire as part of an international study to delineate the HHT phenotype. We identified questionnaires completed by subjects in whom we had identified a mutation in endoglin or ALK1. Further questionnaires were sent to families with known mutations. Data were only included from questionnaires returned by people known to carry disease causing mutations. RESULTS: Questionnaires were completed by 83 subjects with known mutations. Of these, 49 had endoglin mutations (HHT1) and 34 had ALK1 mutations (HHT2). Subjects with HHT1 reported an earlier onset of epistaxis (p=0.01) and telangiectasis (p=0.0001) than those with HHT2. Pulmonary arteriovenous malformations were only reported in the endoglin mutation group in our study (p<0.001). CONCLUSIONS: Our questionnaire based study provides evidence that the HHT phenotype caused by mutations in endoglin (HHT1) is distinct from, and more severe than, HHT caused by mutations in ALK1 (HHT2). This has significant implications for diagnosis, screening, and treatment in the two different forms of HHT, as well as for understanding the pathogenesis of the disease.
BACKGROUND:Hereditary haemorrhagic telangiectasia (HHT) is an autosomal dominant vascular dysplasia characterised by mucocutaneous telangiectasis, epistaxis, gastrointestinal haemorrhage, and arteriovenous malformations in the lung and brain. Causative mutations for HHT have been identified in two genes, endoglin and ALK1, which encode proteins involved in serine-threonine kinase signalling in the endothelial cell. METHODS: A number of people affected with HHT had completed a postal questionnaire as part of an international study to delineate the HHT phenotype. We identified questionnaires completed by subjects in whom we had identified a mutation in endoglin or ALK1. Further questionnaires were sent to families with known mutations. Data were only included from questionnaires returned by people known to carry disease causing mutations. RESULTS: Questionnaires were completed by 83 subjects with known mutations. Of these, 49 had endoglin mutations (HHT1) and 34 had ALK1 mutations (HHT2). Subjects with HHT1 reported an earlier onset of epistaxis (p=0.01) and telangiectasis (p=0.0001) than those with HHT2. Pulmonary arteriovenous malformations were only reported in the endoglin mutation group in our study (p<0.001). CONCLUSIONS: Our questionnaire based study provides evidence that the HHT phenotype caused by mutations in endoglin (HHT1) is distinct from, and more severe than, HHT caused by mutations in ALK1 (HHT2). This has significant implications for diagnosis, screening, and treatment in the two different forms of HHT, as well as for understanding the pathogenesis of the disease.
Authors: M Guerrero-Esteo; P Lastres; A Letamendía; M J Pérez-Alvarez; C Langa; L A López; A Fabra; A García-Pardo; S Vera; M Letarte; C Bernabéu Journal: Eur J Cell Biol Date: 1999-09 Impact factor: 4.492
Authors: X Ma; M Labinaz; J Goldstein; H Miller; W J Keon; M Letarte; E O'Brien Journal: Arterioscler Thromb Vasc Biol Date: 2000-12 Impact factor: 8.311
Authors: G Garcia-Tsao; J R Korzenik; L Young; K J Henderson; D Jain; B Byrd; J S Pollak; R I White Journal: N Engl J Med Date: 2000-09-28 Impact factor: 91.245
Authors: Benjamin N Hunter; Benjamin H Timmins; Jamie McDonald; Kevin J Whitehead; P Daniel Ward; Kevin F Wilson Journal: Laryngoscope Date: 2015-09-15 Impact factor: 3.325
Authors: T G W Letteboer; J J Mager; R J Snijder; B P C Koeleman; D Lindhout; J K Ploos van Amstel; C J J Westermann Journal: J Med Genet Date: 2005-09-09 Impact factor: 6.318
Authors: Mamta Wankhede; Nikita Agarwal; Rodrigo A Fraga-Silva; Casey deDeugd; Mohan K Raizada; S Paul Oh; Brian S Sorg Journal: J Biomed Opt Date: 2010 Jan-Feb Impact factor: 3.170
Authors: Aditya Bharatha; Marie E Faughnan; Helen Kim; Tony Pourmohamad; Timo Krings; Pinar Bayrak-Toydemir; Ludmila Pawlikowska; Charles E McCulloch; Michael T Lawton; Christopher F Dowd; William L Young; Karel G Terbrugge Journal: Stroke Date: 2011-10-27 Impact factor: 7.914